From Trial to Market: Structuring Sponsor-Site Clinical Trial Agreements Under Kenyan Law

A sponsor-site clinical trial agreement is the contract that makes a clinical trial legally workable in Kenya. It sits alongside, not instead of, the regulatory approvals from the Pharmacy and Poisons Board, the ethics review committee, and where applicable NACOSTI. Getting it right matters because it allocates the risks a trial actually generates: who pays if a participant is injured, who owns the data and any resulting invention, who controls publication, and what happens to participants once the trial ends. Sponsors, usually foreign pharmaceutical or biotech companies or the contract research organisations acting for them, and Kenyan sites, whether a hospital, research institute, or individual investigator, each carry distinct obligations the agreement needs to reflect precisely.

Regulatory Approval Sequencing Before the Agreement Is Signed

Kenyan clinical trials need approval from three bodies, in a fixed order. Ethics review comes first: PPB procedure requires a favourable opinion from an accredited ethics review committee before an application reaches the Board. KEMRI’s Scientific and Ethics Review Unit is the most widely used accredited committee, reviewing biomedical research, trials involving investigational drugs and devices, and studies involving vulnerable populations, but it is not the only one, and sponsors should confirm which committee has jurisdiction over the proposed site.

With ethics approval secured, the sponsor applies to the PPB for clinical trial authorisation. Its Expert Committee on Clinical Trials aims to respond within 30 working days under its service charter, and applications are now lodged through the Board’s online portal. Separately, researchers, including foreign researchers, generally need a research licence from the National Commission for Science, Technology and Innovation (NACOSTI) under the Science, Technology and Innovation Act, No. 28 of 2013. NACOSTI treats ethics clearance as a precondition for the licence, not a substitute, and states that its licence does not exempt an applicant from PPB authorisation or other sector-specific approvals. The Health Act, No. 21 of 2017 adds a further layer through its Part XIV provisions on research for health, including the National Health Research Committee and consent protections for research involving minors. A well-drafted agreement schedules each approval in this order and makes site initiation contingent on all three, not just the last one obtained.

Indemnification and Compensation for Trial-Related Injury

The PPB’s Guidelines for the Conduct of Clinical Trials in Kenya place the insurance obligation squarely on the sponsor. They state that the sponsor must provide insurance for all trial participants and ensure the trial institution, any contract research organisation, and the researchers carry sufficient cover. Investigators are separately required to hold their own professional indemnity cover. The current 2022 edition added this insurance requirement explicitly, so sponsors relying on older template agreements should check the clause against the current guideline language.

Informed consent must disclose the compensation and treatment available to a participant if a trial-related injury occurs. This is a substantive drafting point, not a formality: the agreement should specify who pays for treatment while causation is investigated, how a claim is assessed, and whether the sponsor’s indemnity extends to the site’s own negligence or is limited to product-related harm. Kenyan sites should resist indemnity clauses shifting liability back onto the institution beyond its own negligence, since the guidelines place the primary insurance obligation on the sponsor.

Intellectual Property Ownership Over Trial Data and Inventions

The PPB guidelines require that any transfer of ownership of trial data be reported to the Board, so the IP and data ownership clauses carry a regulatory dimension, not just a commercial one. Sponsors typically want to own all data generated at the site, any resulting inventions, background and foreground intellectual property, and the right to file patents globally. Kenyan institutions, particularly public research institutes, increasingly negotiate for at least a royalty-free licence to use the data for non-commercial research and teaching, co-authorship rights, and acknowledgement in patent filings. The agreement should also fix which party handles the Board notification on an ownership transfer, and by when.

Publication Rights and Sponsor Confidentiality

The guidelines recognise that the investigator has both a duty and a right to publish trial results, while requiring that for collaborative and multi-centre studies, publication conditions be set out clearly in the protocol and approved by the relevant regulatory authorities. In practice, agreements resolve the tension between this right and the sponsor’s confidentiality interest through a review-and-delay mechanism: the investigator submits a draft manuscript a fixed number of days beforehand, the sponsor may request removal of confidential information, and it may request a short additional delay to file a patent application, but cannot block publication indefinitely. A clause giving the sponsor an open-ended veto sits uneasily with the guidelines and is worth renegotiating.

Cross-Border Data Transfer and Post-Trial Access

Trial data collected in Kenya, particularly identifiable participant health data, is sensitive personal data under the Data Protection Act, No. 24 of 2019, and its transfer outside Kenya, routine for centralised safety databases, is regulated under sections 48 to 50 of the Act. A transfer needs an adequacy basis, safeguards demonstrated to the Data Commissioner, or explicit consent for sensitive categories. The Office of the Data Protection Commissioner’s guidance on cross-border transfers lists ratification of the African Union’s Malabo Convention, reciprocal data protection agreements, and binding corporate rules as adequacy pathways, and flags that some health-related processing can touch the state’s strategic interests, triggering a requirement to retain a copy of the data on servers in Kenya. Agreements should build in a data processing agreement or standard contractual clauses addressing this, rather than leaving it to a general confidentiality clause.

On the clinical side, the PPB guidelines record a sponsor’s ethical obligation to make a beneficial intervention developed through the research reasonably available to the population or community involved once the trial concludes. The obligation is stated in general terms rather than as a fixed formula, so the agreement should convert it into concrete commitments: continued access to the investigational product for participants who benefited, a defined transition period, and clarity on who bears the cost.